Pascal and Francis Bibliographic Databases


Search results

Your search

kw.\*:("ADP receptor")

Publication Year[py]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Discipline (document) [di]

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Author Country

A-Z Z-A Frequency ↓ Frequency ↑
Export in CSV

Results 1 to 25 of 35

  • Page / 2

Selection :

  • and

Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor geneSTARITZ, Peter; KURZ, Kerstin; STOLL, Monika et al.International journal of cardiology. 2009, Vol 133, Num 3, pp 341-345, issn 0167-5273, 5 p.Article

Unmet needs in oral antiplatelet therapy with ADP receptor blocking agentsHUSTED, Steen.Fundamental & clinical pharmacology. 2009, Vol 23, Num 1, pp 1-9, issn 0767-3981, 9 p.Article

Novel molecular defect in the platelet ADP receptor P2Y12of a patient with haemorrhagic diathesisREMIJN, Jasper A; IJSSELDIJK, Martin J. W; STRUNK, Annuska L. M et al.Clinical chemistry and laboratory medicine. 2007, Vol 45, Num 2, pp 187-189, issn 1434-6621, 3 p.Article

ADP-receptor blockade: A case for personalised pharmacotherapy? : Hot topics in Cardiovascular Cell and Pharmacotherapy (Part I)ZÜRN, Christine S; GEISLER, Tobias; GAWAZ, Meinrad et al.Thrombosis and haemostasis. 2010, Vol 103, Num 3, pp 496-506, issn 0340-6245, 11 p.Article

Thienopyridines in cardiovascular disease : Focus on clopidogrel resistanceSILLER-MATULA, Jolanta; SCHRÖR, Karsten; WOJTA, Johann et al.Thrombosis and haemostasis. 2007, Vol 97, Num 3, pp 385-393, issn 0340-6245, 9 p.Article

Flow dynamics and haemostasisMAZZUCATO, Mario; SANTOMASO, Andrea; CANU, Paolo et al.Annali dell' Istituto superiore di sanità. 2007, Vol 43, Num 2, pp 130-138, issn 0021-2571, 9 p.Article

Platelet function testing and prediction of procedural bleeding risk : High on-treatment platelet reactivityGROVE, Erik L; HOSSAIN, Rashed; STOREY, Robert F et al.Thrombosis and haemostasis. 2013, Vol 109, Num 5, pp 817-824, issn 0340-6245, 8 p.Article

Inter-patient variability and impact of proton pump inhibitors on platelet reactivity after prasugrelARADI, Dániel; KULICZKOWSKI, Wiktor; ATAR, Dan et al.Thrombosis and haemostasis. 2012, Vol 107, Num 2, pp 338-345, issn 0340-6245, 8 p.Article

Platelet function variability and non-genetic causesTENTZERIS, Ioannis; SILLER-MATULA, Jolanta; FARHAN, Serdar et al.Thrombosis and haemostasis. 2011, Vol 105, issn 0340-6245, S60-S66, SUP1Article

Effect of clopidogrel administration to healthy volunteers on platelet phosphorylation events triggered by ADPCONTRERES, Jean O; DUPUY, Evelyne; JOB, Bernard et al.British journal of haematology. 2003, Vol 120, Num 4, pp 633-642, issn 0007-1048, 10 p.Article

Translational platelet research in patients with coronary artery disease: What are the major knowledge gaps?GURBEL, Paul A; ROE, Matthew T; MAGNUS OHMAN, E et al.Thrombosis and haemostasis. 2012, Vol 108, Num 1, pp 12-20, issn 0340-6245, 9 p.Article

Farnesyl pyrophosphate is an endogenous antagonist to ADP-stimulated P2Y12 receptor-mediated platelet aggregationHÖGBERG, Carl; GIDLÖF, Olof; DEFLORIAN, Francesca et al.Thrombosis and haemostasis. 2012, Vol 108, Num 1, pp 119-132, issn 0340-6245, 14 p.Article

Epinephrine-mediated protein kinase C and Rap1b activation requires the co-stimulation of Gz-, Gq-, and Gi-coupled receptorsLOVA, Paolo; GUIDETTI, Gianni Francesco; CANOBBIO, Ilaria et al.Thrombosis and haemostasis. 2011, Vol 105, Num 3, pp 479-486, issn 0340-6245, 8 p.Article

Platelet aggregation and adenosine diphosphate/adenosine triphosphate receptors: A historical perspectivePACKHAM, Marian A; MUSTARD, J. Fraser.Seminars in thrombosis and hemostasis. 2005, Vol 31, Num 2, pp 129-138, issn 0094-6176, 10 p.Article

Bioequivalence and tolerability study of two brands of clopidogrel tablets, using inhibition of platelet aggregation and pharmacodynamic measuresTAKALLAPALLI RAMESH KUMAR RAO; USHA, P. Rani; NAIDU, M. U. R et al.Current therapeutic research. 2003, Vol 64, Num 9, pp 685-696, issn 0011-393X, 12 p.Article

Adherence to protocol and determinants in ST-elevation myocardial infarctionFOURNIER, Nathalie; BESSEREAU, Jacques; CHAMPENOIS, Anne et al.International journal of cardiology. 2013, Vol 166, Num 2, pp 548-549, issn 0167-5273, 2 p.Article

Factors associated with the failure of clopidogrel dose-adjustment according to platelet reactivity monitoring to optimize P2Y12-ADP receptor blockadeBONELLO, Laurent; CAMOIN-JAU, Laurence; MANCINI, Julien et al.Thrombosis research. 2012, Vol 130, Num 1, pp 70-74, issn 0049-3848, 5 p.Article

The P-selectin gene Pro715 allele and low levels of soluble P-selectin are associated with reduced P2Y12 adenosine diphosphate receptor reactivity in clopidogrel-treated patientsGREMMEL, Thomas; KOPP, Christoph W; STEINER, Sabine et al.Atherosclerosis. 2011, Vol 217, Num 1, pp 135-138, issn 0021-9150, 4 p.Article

Comparison of VASP-phosphorylation assay to light-transmission aggregometry in assessing inhibition of the platelet ADP P2Y12 receptorPAMPUCH, Agnieszka; CERLETTI, Chiara; DE GAETANO, Giovanni et al.Thrombosis and haemostasis. 2006, Vol 96, Num 6, pp 767-773, issn 0340-6245, 7 p.Article

Clopidogrel response variability and the advent of personalised antiplatelet therapy: A bench to bedside journeyGURBEL, Paul A; TANTRY, Udaya S.Thrombosis and haemostasis. 2011, Vol 106, Num 2, pp 265-271, issn 0340-6245, 7 p.Article

Immune heparin-induced thrombocytopenia can occur in patients receiving clopidogrel and aspirinSELLENG, Kathleen; SELLENG, Sixten; RASCHKE, Ricarda et al.American journal of hematology. 2005, Vol 78, Num 3, pp 188-192, issn 0361-8609, 5 p.Article

Tailoring Antiplatelet Therapy: A Step Toward Individualized Therapy to Improve Clinical Outcome?LAINE, Marc; CAMOIN-JAU, Laurence; BESSEREAU, Jacques et al.Current pharmaceutical design (Print). 2012, Vol 18, Num 33, pp 5392-5401, issn 1381-6128, 10 p.Article

Cytochrome P450 2C19 loss-of-function polymorphism, but not CYP3A4 IVS10+ 12G/A and P2Y12 T744C polymorphisms, is associated with response variability to dual antiplatelet treatment in high-risk vascular patientsGIUSTI, Betti; GORI, Anna Maria; MARCUCCI, Rossella et al.Pharmacogenetics and genomics (Print). 2007, Vol 17, Num 12, pp 1057-1064, issn 1744-6872, 8 p.Article

Ticagrelor or prasugrel for pre-hospital protocols in STEMI?FOURNIER, Nathalie; TOESCA, Richard; MEYRAN, Daniel et al.International journal of cardiology. 2013, Vol 168, Num 4, pp 4566-4567, issn 0167-5273, 2 p.Article

Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal speciesNIITSU, Yoichi; SUGIDACHI, Atsuhiro; OGAWA, Taketoshi et al.European journal of pharmacology. 2008, Vol 579, Num 1-3, pp 276-282, issn 0014-2999, 7 p.Article

  • Page / 2